BioDelivery Sciences International, Inc. (BDSI)
(Delayed Data from NSDQ)
$4.84 USD
+0.08 (1.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.85 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.84 USD
+0.08 (1.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.85 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
5 Top Rate-Sensitive Stocks to Buy Amid Fed's Rate Cut Hints
by Nalak Das
The Fed has said that adoption of more accommodative policy is gaining ground as some economic developments raised concerns about U.S. and global growth.
Why Is BioDelivery (BDSI) Down 12.3% Since Last Earnings Report?
by Zacks Equity Research
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon
by Swarup Gupta
Trade-war resistant stocks such as biotechs would be the first to benefit from a relief rally.
All You Need to Know About BioDelivery (BDSI) Rating Upgrade to Buy
by Zacks Equity Research
BioDelivery (BDSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BioDelivery (BDSI) Stock Up on Q1 Earnings and Sales Beat
by Zacks Equity Research
BioDelivery (BDSI) incurs narrower-than-expected loss in Q1. Sales surpass the consensus mark. The company raises guidance for 2019.
BioDelivery Sciences International (BDSI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioDelivery (BDSI) delivered earnings and revenue surprises of 37.50% and 0.88%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will BioDelivery Sciences International (BDSI) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for BioDelivery (BDSI) This Earnings Season?
by Zacks Equity Research
Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).
What Makes BioDelivery (BDSI) a New Buy Stock
by Zacks Equity Research
BioDelivery (BDSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BioDelivery (BDSI) Up 7.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M
by Zacks Equity Research
BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.
BioDelivery Sciences International (BDSI) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
BioDelivery Sciences International (BDSI) closed at $5.06 in the latest trading session, marking a -1.65% move from the prior day.
BioDelivery Sciences International (BDSI) Gains But Lags Market: What You Should Know
by Zacks Equity Research
BioDelivery Sciences International (BDSI) closed the most recent trading day at $5.30, moving +0.57% from the previous trading session.
Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse
by Zacks Equity Research
Catalyst (CPRX) reports wider-than-expected loss in the fourth quarter of 2018.
Bristol-Myers & Pfizer Release Phase IV Data on Eliquis
by Zacks Equity Research
Bristol-Myers (BMY) and partner Pfizer ) announce results from the phase IV - AUGUSTUS study evaluating Eliquis (apixaban) versus vitamin K antagonists (VKAs).
BioDelivery (BDSI) Q4 Earnings In Line, Sales Beat, Stock Up
by Zacks Equity Research
BioDelivery Sciences (BDSI) reports in-line loss in Q4. Sales beat the consensus mark. The company issues encouraging guidance for 2019.
Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma
by Zacks Equity Research
Aerie (AERI) gets FDA approval for Rocklatan to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension and announces its 2019 revenue and cash burn outlook.
Alnylam Files Application for Hypertension Candidate in UK
by Zacks Equity Research
Alnylam (ALNY) submits a CTA application to The Medicines and Healthcare products Regulatory Agency in the United Kingdom for ALN-AGT for the treatment of uncontrolled hypertension.
AMAG's Stock Down as Pregnancy Drug Fails in PROLONG Study
by Zacks Equity Research
Shares of AMAG (AMAG) decline almost 17% after the company's pregnancy drug, Makena fails in the post approval PROLONG study.
What Makes BioDelivery Sciences International (BDSI) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Will the Decade-Old Bull Market Momentum Last? 5 Picks
by Nalak Das
After a disappointing 2018, in which all the three major stock indexes closed in the red owing to severe volatility, Wall Street has made a spectacular comeback this year.
What's in Store for BioSpecifics (BSTC) This Earnings Season?
by Zacks Equity Research
BioSpecifics (BSTC) is expected to provide updates on Xiaflex and its pipeline candidates in its fourth quarter earnings call.
What's in the Cards for Corbus (CRBP) This Earnings Season?
by Zacks Equity Research
Corbus (CRBP) is expected to provide updates on its pipeline candidates in the fourth quarter conference call.
REGENXBIO (RGNX) in Focus: Stock Moves 5.1% Higher
by Zacks Equity Research
REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.